TY - JOUR
T1 - The IUPHAR/BPS Guide to PHARMACOLOGY in 2024
AU - Harding, Simon D
AU - Armstrong, Jane F
AU - Faccenda, Elena
AU - Southan, Christopher
AU - Alexander, Stephen P.H.
AU - Davenport, Anthony P
AU - Spedding, Michael
AU - Davies, Jamie A
N1 - Funding Information:
The scope of the database expanded in two Wellcome Trust-funded projects to cover the data-supported druggable human genome () and immunopharmacology. This later aspect was made accessible to immunologists via the dedicated portal, the IUPHAR Guide to IMMUNOPHARMACOLOGY (GtoImmuPdb; https://www.guidetoimmunopharmacology.org ) (). More recently the Guide to MALARIA PHARMACOLOGY (GtoMPdb; https://www.guidetomalariapharmacology.org ) (), was funded as a collaboration between IUPHAR and Medicines for Malaria Venture (MMV; https://www.mmv.org ). Our most recent funded collaboration is with AntibioticDB (ADB; https://www.antibioticdb.com ) (), supported by the Global Antibiotic Research and Development Partnership (GARDP; https://gardp.org/ ) (,). Antimicrobial resistance is one of the top threats to global health ( https://www.who.int/news-room/fact-sheets/detail/antimicrobial-resistance ) and it has been estimated that nearly 1.3 million people die annually as a result of drug-resistant bacteria (), a figure that exceeds both HIV and breast cancer. The AntibioticDB database benefits early-stage research and development by providing valuable references and starting points for future research and for re-development of discontinued agents. Our collaboration with ADB presents an opportunity to strengthen both resources. One aim is to extend antibacterial compound coverage in GtoPdb and to build reciprocal links between the two resources. Through this partnership we will also develop tools that improve access to antibacterial pharmacology.
Funding Information:
International Union of Basic and Clinical Pharmacology; British Pharmacological Society [MED791; ongoing]; GARDP [c-12440474; ongoing]; Medicines for Malaria Venture (Guide to Malaria Pharmacology) [CT-5535; ended Sep 2020]; Antibiotic Research UK [ANTSRG 02/2019; ended November 2020]; Wellcome Trust (Guide to Immunopharmacology) [108420/Z/15/Z; ended October 2018]; American Society for Pharmacology and Experimental Therapeutics; Laboratoires Servier; and The University of Edinburgh; Wellcome Trust-University of Edinburgh Institutional Strategic Support Fund.
Publisher Copyright:
© The Author(s) 2023. Published by Oxford University Press on behalf of Nucleic Acids Research.
PY - 2024/1/5
Y1 - 2024/1/5
N2 - The IUPHAR/BPS Guide to PHARMACOLOGY (GtoPdb; https://www.guidetopharmacology.org) is an open-access, expert-curated, online database that provides succinct overviews and key references for pharmacological targets and their recommended experimental ligands. It includes over 3039 protein targets and 12 163 ligand molecules, including approved drugs, small molecules, peptides and antibodies. Here, we report recent developments to the resource and describe expansion in content over the six database releases made during the last two years. The database update section of this paper focuses on two areas relating to important global health challenges. The first, SARS-CoV-2 COVID-19, remains a major concern and we describe our efforts to expand the database to include a new family of coronavirus proteins. The second area is antimicrobial resistance, for which we have extended our coverage of antibacterials in partnership with AntibioticDB, a collaboration that has continued through support from GARDP. We discuss other areas of curation and also focus on our external links to resources such as PubChem that bring important synergies to the resources.
AB - The IUPHAR/BPS Guide to PHARMACOLOGY (GtoPdb; https://www.guidetopharmacology.org) is an open-access, expert-curated, online database that provides succinct overviews and key references for pharmacological targets and their recommended experimental ligands. It includes over 3039 protein targets and 12 163 ligand molecules, including approved drugs, small molecules, peptides and antibodies. Here, we report recent developments to the resource and describe expansion in content over the six database releases made during the last two years. The database update section of this paper focuses on two areas relating to important global health challenges. The first, SARS-CoV-2 COVID-19, remains a major concern and we describe our efforts to expand the database to include a new family of coronavirus proteins. The second area is antimicrobial resistance, for which we have extended our coverage of antibacterials in partnership with AntibioticDB, a collaboration that has continued through support from GARDP. We discuss other areas of curation and also focus on our external links to resources such as PubChem that bring important synergies to the resources.
U2 - 10.1093/nar/gkad944
DO - 10.1093/nar/gkad944
M3 - Article
SN - 0305-1048
VL - 52
SP - D1438–D1449
JO - Nucleic Acids Research
JF - Nucleic Acids Research
ER -